Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of X4P-001 with toripalimab in advanced or metastatic triple-negative breast cancer
CTR20210708Phase 2Terminated
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mavorixafor, toripalimab in triple-negative breast cancer (TNBC), sponsored by X4 Pharmaceuticals, Inc.. Started Jun 2021; status: terminated.
02
Drugs
mavorixafortoripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20210708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210708.